STOCKS TELEGRAPH

Author: Mahrukh Rehan

  • Vislink Technologies, Inc. (VISL) has increased to 7.11% – What’s driving it high?

    Vislink Technologies, Inc. (VISL) has increased to 7.11% – What’s driving it high?

    Vislink Technologies, Inc. (VISL) has seen an increase of 7.11% in aftermarket. The rally seems to follow discussions on social media sites like Reddit. However, the last trading session concluded at $ 0.8589 with an increase of 0.68%.

    Launch of Mobile Viewpoint Stellar Cam by VISL– What’s up?

    On 18th January 2022, VISL announced that the company has launched a Mobile Viewpoint Stellar Cam. Vislink’s Stellar Cam is a new camera that was created to address the demand for automated sports journalism. It’s weatherproof and sturdy, with ultra-high quality, fast frame rates, and magnification for filming on the field. This statement highlights VISL’s leadership position in leveraging AI-powered technology to reduce the cost of news and sports production.

    Moreover, the Mobile Viewpoint brand has a long history of bringing AI products to market. And Stellar Cam is the latest in that series. Not only this but it’s an important part of IQ Sports Producer. It is the platform for capturing live athletic events without the use of on-site personnel. Lastly, IQ Sports Producer is ideal for mid-tier and lower-tier games and matches, allowing OTT media providers, media rights holders, and production organizations to capture athletic events on a tight budget

    So what?

    VISL began its AI journey by providing clients with a commercially available 4x 4K panoramic surveillance camera. Many high-end broadcast customers desired a camera with a quicker frame rate, variable lenses, and no optical zoom, despite the fact that it was suitable for web streaming. Furthermore, because none were available at the time, the business developed its own broadcast panorama camera, the XCAM. The Stellar Cam is an upgrade of this technology that has a price point similar to the original surveillance camera, but with a lot more functionality and greater quality, including the ability to stream live events at 50/60 frames per second.

    New IP and AI Technology Features and Solutions by VISL – More About it

    On 30th November 2022, VISL reported that Vislink and Mobile Viewpoint product lines have received a number of technical upgrades. They represent major advancements in IP-centric and AI technologies, which are at the core of VISL’s solutions, as well as a rising synergy between the two companies’ offerings. The organization is enabling clients to benefit from this disruptive transformation as a result of the enhancements. Vislink’s great integration with Mobile Viewpoint is demonstrated by these additional functionalities. By linking the Quantum receiver to the Mobile Viewpoint LinkMatrix control platform, VISL allows users to mix wireless footage more readily in a broadcast scenario.

  • Polar Power, Inc. (POLA) stock is rising to 8.99% – Latest News About it

    Polar Power, Inc. (POLA) stock is rising to 8.99% – Latest News About it

    Polar Power, Inc. (POLA) has seen an increase of 8.99% in the aftermarket. However, the last trading session closed at $2.67 with an increase of 0.75%.

    About POLA

    Polar Power, Inc. is a company that develops, produces, and distributes direct current (DC) electric generators, renewable energy systems, and cooling equipment in the US And abroad. This company provides DC base power systems, DC hybrid power systems, and DC solar hybrid power systems.

    Third Quarter 2021 Financial Results – What’s up?

    POLA announced third quarter 2021 financial results on 15th January 2022. The company announced that net sales of the company to be $4.1 million. Not only this but the gross profit came out to be $0.9 million with an incline of 136%. Moreover, the operating expenses declined from $2.0 million to $1.7 million. Lastly, the company experienced a net income of $0.9 million.

    Now what?

    The DC power solutions, which are largely used by telecommunications companies, continue to be in high demand. POLA is also working hard to diversify the customer base. And the company is seeing an increase in sales into non-telecommunications sectors and applications. Moreover, the expansion of 5G networks and the normalization of business activities due to a decrease in COVID-19-related shutdowns and limitations are expected to drive demand for the DC power systems in the telecoms sectors in 2021.

    Furthermore, tier-1 telecommunication clients are already deploying 5G networks, which require much more power at cell sites than 4G networks. Not only this but the usage of 5G technology in IoT, video streaming, and data analytics applications necessitate cell sites to be operational at all times, increasing the requirement for reliable power backup systems. The company also invested in the development of backup power systems with more power, larger engines and alternators, and improved emission control systems in 2021. Last but not the least, POLA anticipates that, in comparison to typical AC power systems, the increasing power demand of 5G networks will expand market prospects for our higher efficient DC power systems.

  • Recon Technology, Ltd. (RCON) stock is going high in aftermarket – What’s happening?

    Recon Technology, Ltd. (RCON) stock is going high in aftermarket – What’s happening?

    Recon Technology, Ltd. (RCON) experienced an increase of 10.26% in aftermarket despite any latest news. However, the last trading session closed at $1.17 with an increase of 16.42%.

    Carbon Neutrality – More About it

    On 24th January 2022, RCON announced that a China-based oil sale company has been assisted by the Future Gas Station (Beijing) Technology Ltd in order to launch one of the best and novel products i.e., Carbon Neutral Box. The CNB is a consumer-side carbon inclusive mini-program. It allows vehicle owners to attain carbon neutrality for the very first time depending on their refueling actions at FGS-served gas stations. Moreover, this is a significant effort to strengthen low-carbon gas station management. Not only this but it will assist vehicle owners in practicing low-carbon consumption, and encourage the use of low-carbon products.

    Analyzing the Launch of Product by RCON

    China had previously issued no consumer-based carbon neutrality certificates. 289 vehicles have received carbon neutral fueling facilities and confirmed certifications at the East Central Road gas station. Furthermore, the company is glad to continue the collaboration with a large oil firm in jointly launching a consumption-side carbon-neutral solution for gas stations. Last but not the least, this is not just a new business investment for FGS, but it also demonstrates the technology services company’s extensive product expertise.

    Integrated Solar Storage by RCON – What’s up?

    RCON reported on 22nd November 2021 that the company has made a huge investment in Shandong Zhong You Yun Xin Information Technology Company Limited. RCON is happy to be one of Zhong You Yun Xin’s shareholders and to collaborate with PetroChina’s Shandong office. This will help explore innovative approaches to revolutionize and upgrade the gas station sector and its profitability model. Moreover, RCON plans on using a software solution based on cloud computing and blockchain technologies to connect the new energy and old energy markets, maximizing the financial benefits of distributed energy while also enhancing gas station operational efficiency and lowering transition costs.

    What’s Next?

    With more than 10,000 gas stations, Shandong is a key region in China for petrochemical energy supplies. All gas stations are being challenged to modernize against the backdrop of a changing business. Moreover, RCON intends to promote efficient gas station management tools and integrated energy supply station solutions. In addition, they serve all vehicle owners with a convenient, economical, and comfortable experience. Last but not the least, the new energy business is the fastest growing industry in China’s “carbon peak and carbon neutral” aim.

  • Savara Inc. (SVRA) stock is experiencing a decrease of 5.13% – Learn why?

    Savara Inc. (SVRA) stock is experiencing a decrease of 5.13% – Learn why?

    Savara Inc. (SVRA) has seen a decrease of 5.13% in the current market. However, the last trading session closed at $1.17 with an increase of 3.54%.

    Third Quarter 2021 Financial Results by SVRA – More About it

    SVRA announced third quarter 2021 financial results on 12th November 2021. The company reported a net loss of $10.5 million with research and development costs of $6.5 million. The cost of screening patients and progressing the IMPALA-2 trial for the molgramostim development program increased by roughly $3.2 million. Moreover, general, and administrative expenses declined by 2 million and reached $3.4 million. Last but not the least, cash and cash equivalents came out to be $171 million.

    What’s new?

    The team is laser-focused on moving forward with the pivotal Phase 3 IMPALA 2 research, which is currently enrolling people. SVRA is also pleased with the progress made in the preceding quarter. Furthermore, an increasing number of locations are assessing and enrolling patients. Not only that, but the EMA accepted the proposed amended PIP, marking a significant regulatory milestone for the company.

    Moreover, despite the unknown impact of COVID-19 and the flu over the winter, the firm remains confident in its prediction of a 20-month recruitment timeline and top-line results by the end of Q2 2024. Finally, the corporation considerably increased inhalation delivery and biological product experience with the addition of Peter Clarke and Charles LaPree to the manufacturing, regulatory, and quality operations.

    Second Quarter 2021 financial Reports by SVRA – How was the quarter?

    SVRA reported second-quarter 2021 financial results on 12th August 2021. The company experienced a net loss of $10.9 million with research and development costs of $1.2 million. Moreover, the general and administrative expenses were recorded as $3.2 million with an incline of 1.2% million. Last but not the least, the company had cash and cash equivalents of $181 million.

    What’s New?

    During the past nine months, the company simplified assets, decreased and reorganized the organization, and drastically strengthened the balance sheet so that they could focus solely on the pivotal Phase 3 IMPALA 2 clinical trial. Furthermore, the trial is progressing as planned, and the timelines are still on schedule, with the first patient dosed just over a month ago, numerous sites now operational, and patients dosed. Importantly, the organization is continuing to incorporate key lessons acquired from the first IMPALA study in order to complete IMPALA 2 as efficiently and as thoroughly as feasible.

  • New Gold Inc. (NGD) stock down in premarket today – Here’s why?

    New Gold Inc. (NGD) stock down in premarket today – Here’s why?

    New Gold Inc. (NGD) experienced a decrease of 1.32% in the premarket. However, the last trading session concluded at $1.52 with a decrease of 5.59%.

    Two New Gold Zones – What’s up?

    On 24th January 2022, Angus Gold Inc. announced assay findings from the last four holes of its 2021 drill program at the Golden Sky Project in Wawa, Ontario. Moreover, the four holes were drilled into a specific section of the property’s massive Banded Iron Formation horizon. It stretches for nearly 5 kilometers. At around 500 meters apart, two of the four holes intersected considerable gold mineralization.

    So what?

    For the first drill program in a largely undiscovered target, these results have well exceeded the company’s expectations. It’s reassuring to hit large gold zones, which suggests the BIF has a large gold-bearing hydrothermal system. Moreover, NGD is dealing with a system that potentially holds large gold resources with over 60 meters. Furthermore, the company has just investigated a small section of the vast BIF horizon within the property.

    Many of Canada’s greatest gold deposits are housed by the BIF, and the company believes that these findings imply that this location has the potential to host mineralization on a comparable scale. Last but not the least, the company will pursue an aggressive 2022 agenda to build on the success of 2021 and explore additional objectives both locally and regionally.

    Sale of the gold stream – Latest news

    On 22nd December 2021, NGD announced that the gold stream which was present on the Blackwater project has been sold for $300 million. Artemis Gold Inc. owns Blackwater entirely, with New Gold retaining the gold stream in exchange for the transfer of Blackwater to Artemis on August 21, 2020.

    About NGD

    New Gold is a Canadian mining company with the Rainy River gold mine and the New Afton copper-gold mine as its significant assets. Artemis Gold Inc., a Canadian-focused investment, has a 5% equity holding in the company. New Gold’s vision is to become the world’s leading intermediate gold business based in Canada.

  • Kintara Therapeutics, Inc. (KTRA) stock is going down – Learn more about it!

    Kintara Therapeutics, Inc. (KTRA) stock is going down – Learn more about it!

    Kintara Therapeutics, Inc. (KTRA) has seen decrease of 1.13% in the premarket despite any news reported by the company. However, the last trading session closed at $0.354 with a decrease of 10.27%.

    Multiyear Research Grant – What’s up?

    KTRA announced on 12th January 2022 that Doctor Anna Golebiewska has been awarded with a multiyear research grant. This research grant is awarded by Luxembourg National Research Fund (FNR) and the Cancer Foundation Luxembourg. In Luxembourg, the FNR is the primary source of funding for research. Moreover, the Cancer Foundation Luxembourg is committed to patient assistance and oncology research by educating cancer patients.

    Now what?

    The acknowledgement and economic assistance from this prestigious organisation for VAL-083 research in Dr. Golebiewska’s laboratory is extremely exciting because it will offer critical data for optimising the clinical use of this first-in-class specific molecular chemotherapeutic. Furthermore, the findings of this study will aid in elucidating possible therapeutic targets for novel co – treatment regimens involving VAL-083, as well as promote the chance to improve therapeutic accuracy in GBM patients.

    First International Site Activation by KTRA – More About it

    On 30th November 2021, KTRA reported about the site activation in GCAR Phase 2/3 Clinical Trial. The speed with which the treatment arm will be implemented in the research continues to excite the Kintara team. Not only this but the company is thrilled to witness GCAR’s outstanding clinical testing consequences, which drew the team to participate in this exciting and highly efficient registrational study. With 31 sites already operational, including the first international site, the company is hopeful to observe GCAR’s extraordinary clinical trial execution capabilities.

    Through response adaptive randomization and a seamless Phase 2/3 design, GBM AGILE is a multinational, novel platform study that aims to find and confirm beneficial medicines for patients with GBM more quickly. The trial will be run under a master protocol that allows numerous medicines. Data from GBM AGILE might be utilized as the basis for new drug applicants and biologics licence applications. This has only been possible because of its novel design and efficient operational infrastructure.

  • Bluejay Diagnostics, Inc. (BJDX) Increases 9.03% in Premarket – Here’s What To Know

    Bluejay Diagnostics, Inc. (BJDX) Increases 9.03% in Premarket – Here’s What To Know

    Bluejay Diagnostics, Inc. (BJDX) has seen a push of 9.03% in the premarket despite any latest news. However, the last trading session closed at $1.55 with a decrease of 8.28%.

    Completion of 90 Subjects in Multicenter Clinical Study

    BJDX announced on 13th January 2022 that in a randomized multicenter clinical trial targeting the fast IL-6 test for COVID-19 patients receiving critical care, 90 subjects were completed. This research uses patient whole blood to produce a unique quick on-site measurement, allowing the company to move forward with a number of activities. Early detection of this susceptible patient population can aid medical care in the implementation of preventative measures. Furthermore, employing IL-6 as an early warning indicator can help healthcare systems save lives by allowing them to sequester crucial resources in time.

    What’s Next?

    This stage of clinical research is critical not just for licensing, but also for demonstrating the Symphony System’s comparative edge in medical care. With all these studies, BJDX will move forward on a range of projects that will emphasize the relevance of IL-6 screening.

    Appointment of Mark Feinberg – Worth it?

    On 5th January 2022, BJDX announced that Mark Feinberg has been appointed as the Chief Medical Advisor. Dr. Feinberg will oversee Bluejay’s clinical development activities and serve as the company’s research and biological advisor. Moreover, the company is glad to introduce Mark to the role of Chief Medical Advisor. BJDX believes that Mark’s significant medical context and corporate strategy leadership ability will be extremely valuable. Lastly, BJDX plans to file its Symphony IL-6 Test Pre-Submission application with the FDA in January 2022.

    Third Quarter 2021 Financial Results

    BJDX reported third-quarter 2021 financial results on 16th December 2021. The company reported that research and development expenses came out to be $442,527. Moreover, general, and administrative expenses were $445,050 and net loss totaled $1,193,381. Last but not the least, the company experienced cash and cash equivalents of $2,330,138.

  • Clearfield, Inc. (CLFD) stock is jumping to 11.41% in premarket – What’s influencing it?

    Clearfield, Inc. (CLFD) stock is jumping to 11.41% in premarket – What’s influencing it?

    Clearfield, Inc. (CLFD) experienced an increase of 11.41% in the premarket because the company reported Fiscal First Quarter 2022 Results. However, the last trading session concluded at $48.65 with a decrease of 3.15%.  

    Fiscal First Quarter 2022 Results by CLFD

    CLFD announced Fiscal First Quarter 2022 Results on 27th January 2022. The company recorded that the net revenue has inclined by 89% owing to an increase of 81 percent in community broadband revenue. Not only this but the net income for the first fiscal quarter of 2022 reached $10.4 million. Furthermore, eco-friendly products continue to be in high demand. As of December 31, 2021, the order backlog was $101 million, $66 million more than that of September 30, 2021.

    Regional broadband service providers in the Community Broadband market account for a substantial portion of the backlog. While traditional broadband providers mostly serve a single state, regional broadband providers serve a multi-state market. Last but not the least, CLFD feels that this is a big growth opportunity for Clearfield because these organizations have not before deployed fiber at this scale.

    Latest News by CLFD

    In a market that tends to adapt and expand with each passing quarter, Clearfield achieved another record-setting financial result in the first quarter of fiscal 2022. CLFD thanks its workers for their unwavering commitment to best-in-class customer service, high-quality goods, and the ability to easily adjust to the customers’ needs. Lastly, CLFD is well-positioned to continue benefiting from the expanding demand for fiber in the business.

    IBD’s 100 Best Companies of 2021 – More About it

    CLFD reported on 6th January 2022 that Investor’s Business Daily (IBD) has named it one of the top 100 companies in 2021. The telecommunications industry is going through a once-in-a-generation investment cycle, and CLFD is able to execute solutions that lower costs and greatly reduce deployment time has made CLFD an obvious choice for operators looking to take advantage of the opportunities. Lastly, CLFD is thrilled to join such an exceptional collection of growth-focused firms on this list for 2021.

  • Everspin Technologies, Inc. (MRAM) has seen a rise of over 10% – What’s driving it higher?

    Everspin Technologies, Inc. (MRAM) has seen a rise of over 10% – What’s driving it higher?

    Everspin Technologies, Inc. (MRAM) has seen a push of 13.41% in the premarket despite any official news released by the company. However, the last trading session closed at $7.98 with a decrease of 5.45%.

    Semi Americas Award – More About it

    MRAM announced on 8th December 2021 that it has been granted the 2021 SEMI Americas Award. Everspin Technologies, based in Chandler, Arizona, was recognized for collaborating with GlobalFoundries. Moreover, Everspin’s new 1-gigabyte (GB) STT-MRAM device is the first of its kind in the world. MRAM is similar to SRAM in terms of performance, but it can keep its charge and data even after one turns off the system.

    What’s Next?

    MRAM is thrilled to win the SEMI America’s Award, which recognizes the STT-MRAM technology’s study, research, and implementation. Furthermore, STT-MRAM is the industry’s most reliable and adaptable non-volatile memory, promising faster data access. Last but not the least, the company thanks to the team of MRAM who have worked tirelessly for years to bring this to market.

    Third Quarter 2021 Financial Results by MRAM – What’s new?

    MRAM reported results of the third quarter of 2021 on 11th November 2021. Revenue climbed by 25% to $14.8 million in the third quarter more than the previous quarter. When compared to the $10.1 million in sales in Q3 of 2020, the company noticed a 46.5 percent gain.

    Moreover, the company recorded a record net income of $880k, culminating in a year-to-date net income of $676k for the fiscal year 2021. This compares to a net loss of $3.9 million in the third quarter of 2020, and a year-to-date net loss of $6.9 million for the nine months ending September 30, 2020.

    The third quarter of 2021 saw a gross margin of 57.1 percent, less than 60.8 percent the previous quarter, and 23.0 percent in the third quarter of 2020. Due to increases in research and development, sales and marketing, and administrative expenditures, GAAP operating expenses for the third quarter of 2021 climbed to $7.4 million, up from $6.7 million in the second quarter of 2021.

  • Provention Bio, Inc. (PRVB) stock is moving up by 22.06% in after hours – Why is this happening?

    Provention Bio, Inc. (PRVB) stock is moving up by 22.06% in after hours – Why is this happening?

    Provention Bio, Inc. (PRVB) experienced an increase of 22.06% in aftermarket following the announcement of Resubmitting Biologics License Application for Clinical Type 1 Diabetes. However, the last trading session concluded at $3.4 with a decrease of 6.59%.

    Resubmitting Biologics License Application – What’s up?

    On 27th January 2022, PRVB announced that it has resubmitted the teplizumab Biologics License Application (BLA) for the control of clinical type 1 diabetes. In the BLA resubmission, the Company will present a hybrid 14-day treatment plan to alleviate the FDA’s comparability concerns. This will be based on the Company and FDA’s agreed-upon PK modeling and the Company’s experience with various dosages and regimens evaluated in earlier clinical studies. According to an agreement reached with the FDA at a Type A meeting conducted in August last year, the BLA resubmission will contain responses to the CRL’s Chemical, Manufacturing, and Controls (CMC) and quality control concerns. In the first quarter, PRVB expects to be able to resubmit the BLA.

    Now what?

    PRVB is ecstatic to be working on resubmitting the teplizumab BLA, which will move the firm one step closer to its goal of giving teplizumab to family members at risk of developing end-stage, insulin-dependent type 1 diabetes while taking into account the FDA’s feedback.

    Furthermore, the company appreciates the FDA’s Breakthrough Therapy Designation team’s high level of participation and assistance during this regulatory review process (BTD).

    Not only that, but the company plans to resubmit the BLA as quickly as possible, assisting the FDA with its review and decision. The team continues to prepare PRVB for a future launch of teplizumab with carefully controlled spending and planning.

    Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 – Latest News

    PRVB stated on 20th January 2022 that Phase 2a PREVAIL-2 study of PRV-3279 has been started. PRV-3279 combines two important immune protein targets to change their interactions in a smart way. Moreover, CD32B is a natural activator of B cells and CD79B is part of the B cell receptor. Arthritis and Clinical Immunology Program has led global efforts to produce more interpretable trials. The use of a B cell gene profile to stratify and pre-define subsets in PREVAIL-2 helps to identify patients who will benefit from PRV-3279 treatment in the future.

    What’s Next?

    PRV-3279 has an elegant mode of action which is to intercept and ameliorate the pathophysiology of lupus. In addition, PRVB believes that PRV-3279 allows for fast suppression of active B cells while sparing non-activated B cells from depletion. Last but not the least, PREVAIL-2 data is expected to be available in the first half of 2024.